Logicbio Therapeutics Inc (LOGC) Gets a Buy Rating from Chardan Capital
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Logicbio Therapeutics Inc (LOGC) today and set a price target of $20. The company’s shares closed last Monday at $8.01, close to its 52-week low of $6.70.
According to TipRanks.com, Livshits is a 3-star analyst with an average return of 7.2% and a 56.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Logicbio Therapeutics Inc with a $23 average price target, a 152.2% upside from current levels. In a report issued on August 13, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.07 and a one-year low of $6.70. Currently, Logicbio Therapeutics Inc has an average volume of 19.51K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LogicBio Therapeutics, Inc. is a genome editing company, which engages in developing medicines to treat rare diseases in patients with significant unmet medical need. It focuses on the commercialization of specific genome editing and integration of the therapeutic transgene.